Natera co-founder Sheena Jonathan sells $826,326 in stock

AUSTIN, Texas—Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), an $18.1 billion market cap healthcare company with impressive 56.8% revenue growth over the last twelve months, recently executed a series of stock sales, according to a recent SEC filing. On April 3 and 4, Jonathan sold a total of 4,725 shares of Natera’s common stock, generating approximately $826,326. The shares were sold at prices ranging from $132.0414 to $141.28 per share.

These transactions were carried out under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks in a manner that complies with insider trading laws. Following these sales, Jonathan holds 255,249 shares directly and additional shares indirectly through the Caraluna 1 and 2 Trusts. According to InvestingPro, which offers comprehensive analysis of over 1,400 US stocks, Natera maintains a strong financial position with a current ratio of 4.0.

The sales reflect a strategic move by Jonathan, who remains a significant stakeholder in the company. Natera, a leader in medical laboratory services, continues to be a prominent player in the healthcare sector, with analysts setting price targets as high as $251 and the stock delivering a 38.4% return over the past year despite current overvalued levels.

In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with a revenue of $476 million, significantly higher than the predicted $409.89 million. The company also posted a narrower-than-anticipated loss per share of -$0.41 compared to the forecasted -$0.49. Analysts from Canaccord Genuity and TD Cowen have maintained their Buy ratings on Natera, with both firms setting a price target of $195. Canaccord Genuity raised its target from $180, following Natera’s strong fourth-quarter performance and optimistic guidance for 2025, which suggests a year-over-year revenue growth in the mid-20% range.

Additionally, Natera has launched the HEROES clinical trial in France to explore treatment de-escalation in metastatic HER2+ breast cancer patients, potentially impacting future cancer treatment strategies. The trial is funded by the French Ministry of Health and sponsored by Unicancer. In the analyst community, TD Cowen highlighted Natera’s promising guidance for 2025, with sales projections exceeding consensus estimates by approximately 5%. The firm noted potential growth drivers such as increased sales, higher gross margins, and strategic operational expenditures. These recent developments reflect Natera’s robust financial performance and strategic initiatives in the healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.